Targeting TAG-72 in cutaneous T cell lymphoma.

Current monoclonal antibody-based treatment approaches for cutaneous T cell lymphoma (CTCL) rely heavily on the ability to identify a tumor specific target that is essentially absent on normal cells. Herein, we propose tumor associated glycoprotein-72 (TAG-72) as one such target. TAG-72 is a mucin-associated, truncated O-glycan that has been identified as a chimeric antigen receptor (CAR)-T cell target in solid tumor indications. To date, TAG-72 targeting has not been considered in the setting of hematological malignancies. CD3 TAG-72 expression was significantly higher on total CD3 This study shows the first evidence of TAG-72 as a possible target for the treatment of CTCL.

Informations de copyright

© 2024 The Authors. Published by Elsevier Ltd.

Déclaration de conflit d'intérêts

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: The research described in this paper was funded by Cartherics Pty Ltd. All authors except H.M.P., C.V.D.W. and R.T, are paid employees of Cartherics and hold options and/or equity in the company. R.L.B, A.O.T and I.T.N are key Cartherics executives and H.M.P. is a member of the company's Scientific Advisory Board. V.J.E, R.L.B, I.T.N, H.M.P and A.O.T are inventors on Cartherics-owned patent applications related to this work.